Evidence map›Paper›PMID 32352681›Full record

ArticleClinical and translational gastroenterology2020

Antifibrotic Effects of the Thiazolidinediones in Eosinophilic Esophagitis Pathologic Remodeling: A Preclinical Evaluation.

Quan M Nhu, Lance Hsieh, Lucas Dohil, Ranjan Dohil, Robert O Newbury, Richard Kurten, Fouad J Moawad, Seema S Aceves

Open access · goldAbstract read
In one paragraph

Article in Clinical and translational gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Quan M NhuDivision of Gastroenterology and Hepatology, Department of Medicine, Scripps Clinic, La Jolla, California, USA.
Lance HsiehDivision of Allergy and Immunology, Departments of Pediatrics and Medicine, University of California, San Diego, La Jolla, California, USA.
Lucas DohilDivision of Allergy and Immunology, Departments of Pediatrics and Medicine, University of California, San Diego, La Jolla, California, USA.
Ranjan DohilDivision of Gastroenterology and Nutrition, Department of Pediatrics, University of California, San Diego, La Jolla, California, USA.
Robert O NewburyRady Children's Hospital, San Diego, San Diego, California, USA.
Richard KurtenDepartment of Physiology and Biophysics, University of Arkansas for Medical Sciences, Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, USA.
Fouad J MoawadDivision of Gastroenterology and Hepatology, Department of Medicine, Scripps Clinic, La Jolla, California, USA.
Seema S AcevesDivision of Allergy and Immunology, Departments of Pediatrics and Medicine, University of California, San Diego, La Jolla, California, USA.
University of California, San Diego · USRady Children's Hospital-San Diego · USScripps Clinic · US

Funding

Scripps Translational Science InstituteUL1TR001114 · NCATS · SCRIPPS RESEARCH INSTITUTE, THE · PI TOPOL, ERIC JEFFREY · 2013 to 2017
$24.0M
TRAINING (CAREER DEVELOPMENT) COMPONENTU54AI117804 · NIAID · CINCINNATI CHILDRENS HOSP MED CTR · PI Nirmala P Gonsalves · 2014 to 2026
$18.5M
Mechanisms of tissue damage leading to chronic allergic eosinophilic esophagitisR01AI092135 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ACEVES, SEEMA S · 2011 to 2020
$4.4M
Scripps Translational Science InstituteKL2TR001112 · NCATS · SCRIPPS RESEARCH INSTITUTE, THE · PI TOPOL, ERIC JEFFREY · 2013 to 2017
$3.0M
Mentoring Patient Oriented Research in Allergic Eosinophilic Gastrointestinal DisordersK24AI135034 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ACEVES, SEEMA S · 2018 to 2022
$898k
NCATS NIH HHS KL2 TR001112NCATS NIH HHS L30 TR002507NCATS NIH HHS UL1 TR001114NIAID NIH HHS K24 AI135034NIAID NIH HHS R01 AI092135NIAID NIH HHS U54 AI117804
6 · The paper itself

Abstract

introductionEosinophilic esophagitis (EoE) is a T-helper 2 (Th2), eosinophilic disease associated with pathologic tissue remodeling that leads to end-organ dysfunction. During early-stage disease, inflammation and subepithelial fibrosis are coupled and reversible, but in late-stage or therapy-resistant disease, there can be uncoupling of these features with progressive esophageal rigidity and strictures contributing to clinical dysphagia and food impactions. No current pharmacotherapeutic interventions directly target esophageal fibrosis. Based on the ability of the thiazolidinediones (TZD) to regulate intestinal and hepatic fibrosis, we tested the antifibrotic effects of the TZDs, rosiglitazone and pioglitazone, in preclinical studies using primary human esophageal fibroblasts.

methodsPrimary fibroblasts isolated from normal or EoE esophagi were treated with transforming growth factor (TGF)-β1 in the absence or presence of TZDs and, in some experiments, without or with budesonide and analyzed by quantitative real-time PCR and immunoblotting. Immunohistochemical analysis of human esophageal biopsies was performed.

resultsEoE esophageal biopsies and esophageal fibroblasts expressed higher levels of the TZD receptor, peroxisome proliferator-activated receptor-γ (PPAR-γ), than normal controls. PPAR-γ was inducible by the Th2 cytokine, interleukin 4 (IL-4). TZD significantly reduced TGF-β1-induced myofibroblast and fibrotic gene and protein expression preferentially in EoE, but not normal esophageal fibroblasts. In esophageal fibroblasts, TGF-β1 increased phosphorylated Smad2/3 and p38, but TZDs preferentially inhibited p38 phosphorylation, suggesting signaling pathway-specific effects. The TZDs were more potent than budesonide at decreasing collagen-1α1 expression. DISCUSSION: The TZDs preferentially exert antifibrotic effects in TGF-β1-activated EoE fibroblasts and provide a preclinical foundation for further investigation of the potential of the TZDs in EoE pathologic remodeling.

Indexed as

BiopsyBudesonideCells, CulturedDrug Evaluation, PreclinicalEosinophilic EsophagitisEsophagusFibrosisGene Expression RegulationHumansInterleukin-4MyofibroblastsPioglitazonePPAR gammaPrimary Cell CultureRosiglitazoneSignal TransductionBudesonideIL4 protein, humanInterleukin-4PioglitazonePPAR gammaPPARG protein, humanRosiglitazoneTGFB1 protein, humanTransforming Growth Factor beta1

Identifiers

PMID32352681
PMCPMC7263661
OpenAlexW3016289317

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.